TY - JOUR T1 - Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit JF - Anticancer Research JO - Anticancer Res SP - 3109 LP - 3119 DO - 10.21873/anticanres.15095 VL - 41 IS - 6 AU - SHOGO NAKAMOTO AU - MASAHIKO IKEDA AU - SHINICHIRO KUBO AU - MARI YAMAMOTO AU - TETSUMASA YAMASHITA Y1 - 2021/06/01 UR - http://ar.iiarjournals.org/content/41/6/3109.abstract N2 - Background/Aim: We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS). Patients and Methods: We retrospectively investigated 94 advanced breast cancer (ABC) patients who underwent eribulin therapy between July 2011 and June 2020. Results: The multivariate analysis showed that high baseline ALC and low NLR were independent predictive markers for overall survival (OS) (p=0.007 and p=0.011, respectively) and PPS (p=0.005 and p=0.007, respectively). Dynamic changes in ALC were also associated with OS and PPS (p=0.015, and p=0.026, respectively) and were an independent predictive marker for PPS (p=0.021). Conclusion: Baseline ALC and NLR and dynamic changes in ALC during eribulin therapy were significantly associated with survival benefit including PPS for patients with ABC. ER -